Precision Business Insights
Portfolio

 

Research Reports

Gastroparesis Management Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Gastroparesis Management Market: Gastroparesis is also called as delayed gastric emptying, is a disorder of stomach that hinder the movement of food from stomach to small intestine. Generally, muscles of the GI tract controlled by the vagus nerve, that contract to move the food contents throughout the GI tract. Gastroparesis occurs when vagus nerve damaged by illness or the injury which leads to slower movement of food contents from the stomach to the small intestine. Majority of people with gastroparesis have idiopathic gastroparesis of which cause is unknown. Diabetes is commonly known the cause of gastroparesis. Elevated sugar levels in diabetics believed to cause damage of vagus nerve and other causes of gastroparesis include gastric surgery, Parkinson’s diseases, and multiple sclerosis. Gastroparesis generally found in females than males.

 

Market Outline: Global Gastroparesis Management Market

 

Rising prevalence of diabetes and gastroparesis, increasing gastroparesis awareness among healthcare professionals expected to propel market for gastroparesis management market over the forecast period. Moreover, rising clinical development candidates for treating gastroparesis is expected to fuel the market revenue for gastroparesis management market. For instance, as of now, there are around six drug candidates in clinical development which act by different mechanisms and route of administration. However, a dearth of specific treatment options, large medical unmet need, and lack of gastroparesis management guidelines expected to hamper the Gastroparesis Management Market over the forecast period.

 

Gastroparesis Management market has been segmented on the basis of cause, gastroparesis type, intervention type, distribution channel, and region

 

 

Based on intervention type, Gastroparesis Management Market segmented as follows:

  • Drugs
    • Prokinetic Agents
    • Antiemetics
    • Botulinum Toxin
  • Surgical Treatment
    • Percutaneous Endoscopic Gastroscopic Kit
    • Gastric Electrical Stimulation Devices
    • Parenteral Nutrition

 

Based on a cause, Gastroparesis Management Market segmented as follows:

  • Idiopathic Gastroparesis
  • Diabetic Gastroparesis
  • Surgery
  • Nervous System Disorders
  • Others

 

Based on gastroparesis type, Gastroparesis Management Market segmented as follows:

  • Acute Gastroparesis
  • Recurrent gastroparesis

 

Based on distribution channel, Diabetic Gastroparesis Management market segmented as follows:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • E-Commerce

 

Players in Gastroparesis Management Market developing newer formulations like the oral route of administration to bypass the stomach and to produce predictable results. For instance, Evoke Pharma developing intranasal metoclopramide i.e. EVK-001, to treat acute and recurrent gastroparesis. Several interventional drugs for treating gastroparesis are in clinical development. Currently, Metocloparamide is the only drug approved for treating gastroparesis by US FDA.

 

Gastroparesis management market has been segmented into five regions Viz. North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. North America gastroparesis market is driven by increasing prevalence of disease and potentially 12-16 Mn patients are believed to suffering from gastroparesis in the region. Asia Pacific market expected to grow at significant rate owing to the higher prevalence of diabetes in the region. Asian countries contribute around 60% of the world diabetes population which is expected to drive the market revenue growth. Europe market for gastroparesis management expected to grow at moderate CAGR over forecast period.

 

Some of the players in the Gastroparesis Management Market include Abbott Laboratories, Salix Pharmaceuticals, Inc., Janssen Global Services, LLC, Medtronic, Kimberly-Clark Corporation, C. R. Bard, Inc., Boston Scientific Corporation, Rhythm Pharmaceuticals, Inc., and Evoke Pharma to name a few.

 

  • In December 2016, Theravance Biopharma received FDA Fast Track Designation for Velusetrag (TD-5108) for Idiopathic and Diabetic Gastroparesis which is in Phase 2b.

 

Report Outline:

  • The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
  • The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments, and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • Abbott Laboratories
  • Salix Pharmaceuticals, Inc.
  • Janssen Global Services, LLC
  • Medtronic
  • Kimberly-Clark Corporation
  • C. R. Bard, Inc.
  • Boston Scientific Corporation
  • Rhythm Pharmaceuticals, Inc.
  • Evoke Pharma

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

$ 3,000.00$ 8,900.00
Clear selection

Select License Type

Databank $ 3,000.00
spinner
Single User $ 4,400.00
spinner
Multiple User $ 6,600.00
spinner
Corporate User $ 8,900.00
spinner
buy now spinner
FacebookTwitterLinkedinEmail

Our Clients

Testimonials